Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

GB-0669

Monoclonal antibody · developed by Generate Biomedicines

Phase 1 Most advanced trial (none active)

GENB Developer

1 Registered trials

What is GB-0669?

GB-0669 is an agent given as a single intravenous infusion.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Monoclonal antibody
Therapy area: Infectious disease
Developer: Generate Biomedicines (GENB)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07050511	Phase 1	SARS CoV-2	Completed	GENB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

SARS CoV-2

More from Generate Biomedicines

GB-0895 Phase 3

Sources

ClinicalTrials.gov NCT07050511

Updated Oct 11, 2026. Something wrong or missing? Report it on the GENB page.

Follow GENB, the company behind GB-0669

See GENB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GENB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z